Cargando…

Genomic mutations and histopathologic biomarkers in Y(90) radioembolization for chemorefractory colorectal liver metastases

BACKGROUND: To investigate mutational load and histologic biomarkers as prognostic factors in patients with chemorefractory colorectal liver metastases (CRLM) treated with Y-90 radioembolization therapy. MATERIALS AND METHODS: Single institution retrospective study of patients with CRLM who received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dendy, Meaghan S., Ludwig, Johannes M., Kokabi, Nima, Stein, Stacey M., Lacy, Jill, Hochster, Howard S., Kim, Hyun S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126695/ https://www.ncbi.nlm.nih.gov/pubmed/30197760 http://dx.doi.org/10.18632/oncotarget.25992

Ejemplares similares

Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity after radioembolization with yttrium-90 resin microspheres
por: Melucci, Elisa, et al.
Publicado: (2013)

Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla
por: Sotirchos, Vlasios S., et al.
Publicado: (2014)

Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer
por: Raval, Mihir, et al.
Publicado: (2014)

Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence
por: Dendy, Meaghan S., et al.
Publicado: (2017)

Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
por: Villalobos, Alexander, et al.
Publicado: (2021)

Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization
por: Xing, Minzhi, et al.
Publicado: (2018)

Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity
por: Zhang, Yue, et al.
Publicado: (2015)

Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience
por: Nace, Gary W., et al.
Publicado: (2011)

Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases
por: Tsang, Erica S., et al.
Publicado: (2020)

Role of Yttrium-90 Radioembolization for Colorectal Hepatic Metastasis
por: Kim, Hyo-Cheol
Publicado: (2022)

Yttrium-90 Microsphere Radioembolization for Treatment of Lung Cancer Hepatic Metastases
por: Gaba, Ron C., et al.
Publicado: (2012)

Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate Cancer
por: Bunck, Alexander C., et al.
Publicado: (2017)

The Predictive Value of SPECT/CT imaging in colorectal liver metastases response after (90)Y-radioembolization
por: Piasecki, Piotr, et al.
Publicado: (2018)

Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review
por: Alonso, JC, et al.
Publicado: (2023)

Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
por: Puleo, Luciana, et al.
Publicado: (2022)

Case Report of Cirrhosis following Yttrium-90 Radioembolization for Pancreatic Neuroendocrine Liver Metastases
por: Loree, Jonathan M., et al.
Publicado: (2016)

Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response
por: Rosenbaum, C. E. N. M., et al.
Publicado: (2016)

Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies
por: Janowski, E., et al.
Publicado: (2017)

Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review
por: Feretis, Michael, et al.
Publicado: (2020)

Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology
por: Lu, Sen, et al.
Publicado: (2021)

Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with (90)Y-Microspheres for Unresectable Liver Metastases
por: Smits, Maarten L. J., et al.
Publicado: (2013)

Side Effects of Yttrium-90 Radioembolization
por: Riaz, Ahsun, et al.
Publicado: (2014)

Mode of progression after radioembolization in patients with colorectal cancer liver metastases
por: van Roekel, Caren, et al.
Publicado: (2020)

Radioembolization treatment for liver metastases
por: Kiszkaą, Joanna, et al.
Publicado: (2017)

Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond
por: Elsayed, Mohammad, et al.
Publicado: (2021)

Correction: Clinical and Laboratory Toxicity after Intra-Arterial Radioembolization with (90)Y-Microspheres for Unresectable Liver Metastases
por: Smits, Maarten L. J., et al.
Publicado: (2013)

Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study
por: Kokabi, Nima, et al.
Publicado: (2023)

Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy
por: Nance, Michael E., et al.
Publicado: (2020)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
por: Saini, Aman, et al.
Publicado: (2019)

Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

Readministration of Cancer Drugs in a Patient with Chemorefractory Metastatic Colorectal Cancer
por: Kawagoe, Tetsuro, et al.
Publicado: (2020)

Assessment of Treatment Response Following Yttrium-90 Transarterial Radioembolization of Liver Malignancies
por: Adcock, Charles S, et al.
Publicado: (2018)

Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer
por: Yu, Jeong Il, et al.
Publicado: (2016)

Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases
por: Khin, Nyan Y., et al.
Publicado: (2022)

Radioembolization and the Dynamic Role of (90)Y PET/CT
por: Pasciak, Alexander S., et al.
Publicado: (2014)

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
por: Lee, Victor Ho-Fun, et al.
Publicado: (2015)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7nejsitqtqmbr5pso9i3t66u4r